Next Article in Journal
Smoking Behaviours of Current Cancer Patients in Canada
Previous Article in Journal
Management of Small-Cell Lung Cancer with Radiotherapy—A Pan-Canadian Survey of Radiation Oncologists
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 23
Issue 3
10.3747/co.23.3120
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer

by
B. Melosky
1,*,
J. Agulnik
2,3,4,5,6,
R. Albadine
2,3,4,5,6,
S. Banerji
7,
D.G. Bebb
8,9,
D. Bethune
10,
N. Blais
2,3,4,5,6,
C. Butts
8.9,
P. Cheema
11,12,13,14,
P. Cheung
11,12,13,14,
V. Cohen
2,3,4,5,6,
J. Deschenes
8,9,
D.N. Ionescu
1,
R. Juergens
11,12,13,14,
S. Kamel-Reid
11,12,13,14,
S.A. Laurie
,
G. Liu
,
W. Morzycki
10,
M.S. Tsao
11,12,13,14,
Z. Xu
10 and
V. Hirsh
2,3,4,5,6add Show full author list remove Hide full author list
1
British Columbia Canc Agcy, Vancouver Centre, Vancouver, BC V5Z 4E6, Canada
2
Jewish General Hospital, McGill University, Montreal, QC, Canada
3
chum–Hôpital St-Luc, Montreal, QC, Canada
4
chum–Hôpital Notre-Dame, Montreal, QC, Canada
5
Royal Victoria Hospital, Montreal, QC, Canada
6
Segal Cancer Centre and Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada
7
CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada
8
Tom Baker Cancer Centre, Calgary, AB, Canada
9
ross Cancer Institute and University of Alberta, Edmonton, AB, Canada
10
QEII Health Sciences Centre, Halifax, NS, Canada
11
Sunnybrook Odette Cancer Centre, Toronto, ON, Canada
12
Juravinski Cancer Centre, Hamilton, ON, Canada
13
University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada
14
The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(3), 196-200; https://doi.org/10.3747/co.23.3120
Submission received: 1 March 2016 / Revised: 4 April 2016 / Accepted: 7 May 2016 / Published: 1 June 2016

Abstract

Anaplastic lymphoma kinase (alk) is an oncogenic driver in non-small-cell lung cancer (nsclc). Chromosomal rearrangements involving the ALK gene occur in up to 4% of nonsquamous nsclc patients and lead to constitutive activation of the alk signalling pathway. ALK-positive nsclc is found in relatively young patients, with a median age of 50 years. Patients frequently have brain metastasis. Targeted inhibition of the alk pathway prolongs progression-free survival in patients with ALK-positive advanced nsclc. The results of several recent clinical trials confirm the efficacy and safety benefit of crizotinib and ceritinib in this population. Canadian oncologists support the following consensus statement: All patients with advanced nonsquamous nsclc (excluding pure neuroendocrine carcinoma) should be tested for the presence of an ALK rearrangement. If an ALK rearrangement is present, treatment with a targeted alk inhibitor in the first-line setting is recommended. As patients become resistant to first-generation alk inhibitors, other treatments, including second-generation alk inhibitors can be considered.
Keywords: ALK; anaplastic lymphoma kinase; non-small-cell lung cancer; molecular testing; targeted inhibition ALK; anaplastic lymphoma kinase; non-small-cell lung cancer; molecular testing; targeted inhibition

Share and Cite

MDPI and ACS Style

Melosky, B.; Agulnik, J.; Albadine, R.; Banerji, S.; Bebb, D.G.; Bethune, D.; Blais, N.; Butts, C.; Cheema, P.; Cheung, P.; et al. Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer. Curr. Oncol. 2016, 23, 196-200. https://doi.org/10.3747/co.23.3120

AMA Style

Melosky B, Agulnik J, Albadine R, Banerji S, Bebb DG, Bethune D, Blais N, Butts C, Cheema P, Cheung P, et al. Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer. Current Oncology. 2016; 23(3):196-200. https://doi.org/10.3747/co.23.3120

Chicago/Turabian Style

Melosky, B., J. Agulnik, R. Albadine, S. Banerji, D.G. Bebb, D. Bethune, N. Blais, C. Butts, P. Cheema, P. Cheung, and et al. 2016. "Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer" Current Oncology 23, no. 3: 196-200. https://doi.org/10.3747/co.23.3120

Article Metrics

Back to TopTop